Status:
COMPLETED
Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
Lead Sponsor:
Eli Lilly and Company
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-76 years
Phase:
PHASE1
Brief Summary
The goals of this study are to: Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these levels to the amount of...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients must have schizophrenia or schizoaffective disorders.
- Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent.
- Patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry.
- Female patients must not be pregnant or breast-feeding.
- Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or schizoaffective disorder.
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00094640
Last Update
July 19 2006
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
Adelaide, South Australia, Australia
2
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
Kortenberg, Belgium
3
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
Rio de Janeiro, Rio de Janeiro, Brazil
4
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
Zagreb, Croatia